{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:57:04Z","timestamp":1781647024540,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["ZIA HD009001"],"award-info":[{"award-number":["ZIA HD009001"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["ZIA DC000064"],"award-info":[{"award-number":["ZIA DC000064"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low-vision rehabilitative support for children with multiple-disability conditions is underexplored. We conduct a pilot study of an assistive device in children with CLN3 disease, a multisystemic pediatric blindness and neurodegenerative condition. The prospective, pilot study (NCT04974307) evaluated the safety, feasibility and preliminary efficacy of the OrCam MyEye 2 in aiding daily living tasks. We used multimodal assessments of feasibility and efficacy to assess nine participants with CLN3 disease and one with non-CLN3 low vision (age 8.1-17.4 years; females:males 2:8) at baseline (Day 1, without the device) and Day 5 (with the device).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Surveyed parents and affected children reported desire for future research addressing the vision loss in CLN3 disease, and lower quality of life in vision-related domains. One grade 1 adverse event was recorded during the study. Feasibility and Function assessments showed that &gt; 90% of evaluable participants scored above thresholds on feasibility assessments and &gt; 25% had improved scores and performance time on device-specific tasks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The data provide indications for the safety, feasibility and task-specific efficacy for the OrCam MyEye 2. They support further, including longitudinal, evaluation and consideration of such optic-to-audio devices as part of the toolbox for low vision therapy for children with multiple disabilities such as CLN3 disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      clinicaltrials.gov, NCT04974307. Registered 23 July 2021,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/\" ext-link-type=\"uri\">https\/\/clinicaltrials.gov\/study\/NCT04974307<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04319-0","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:26:58Z","timestamp":1775204818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective pilot safety, feasibility study of an optic-to-audio device for children with CLN3 disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Thuy Tien","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisha","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibukun","family":"Agbede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadih M.","family":"Zein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laryssa A.","family":"Huryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Magone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colby","family":"Chlebowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Thurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-0493","authenticated-orcid":false,"given":"An N.","family":"Dang Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"3","key":"4319_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S2352-4642(20)30366-7","volume":"5","author":"LJ Teoh","year":"2021","unstructured":"Teoh LJ, Solebo AL, Rahi JS, British Childhood Visual I, Blindness Study Interest G. Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study. Lancet Child Adolesc Health. 2021;5(3):190\u2013200.","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"4319_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/archdischild-2012-303002","volume":"99","author":"AL Solebo","year":"2014","unstructured":"Solebo AL, Rahi J. Epidemiology, aetiology and management of visual impairment in children. Arch Dis Child. 2014;99(4):375\u20139.","journal-title":"Arch Dis Child"},{"issue":"6","key":"4319_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1046\/j.1365-2214.2003.00369.x","volume":"29","author":"NM Flanagan","year":"2003","unstructured":"Flanagan NM, Jackson AJ, Hill AE. Visual impairment in childhood: insights from a community-based survey. Child Care Health Dev. 2003;29(6):493\u20139.","journal-title":"Child Care Health Dev"},{"issue":"4","key":"4319_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.oret.2019.11.005","volume":"4","author":"GA Wright","year":"2020","unstructured":"Wright GA, Georgiou M, Robson AG, Ali N, Kalhoro A, Holthaus SK, et al. Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy. Ophthalmol Retina. 2020;4(4):433\u201345.","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"4319_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1212\/01.wnl.0000169019.41332.8a","volume":"65","author":"FJ Marshall","year":"2005","unstructured":"Marshall FJ, de Blieck EA, Mink JW, Dure L, Adams H, Messing S, et al. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology. 2005;65(2):275\u20139.","journal-title":"Neurology"},{"issue":"3","key":"4319_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ejpn.2012.10.011","volume":"17","author":"AK Nielsen","year":"2013","unstructured":"Nielsen AK, Ostergaard JR. Do females with juvenile ceroid lipofuscinosis (Batten disease) have a more severe disease course? The Danish experience. Eur J Paediatr Neurol. 2013;17(3):265\u20138.","journal-title":"Eur J Paediatr Neurol"},{"issue":"11","key":"4319_CR7","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.bbadis.2012.08.012","volume":"1832","author":"M Haltia","year":"2013","unstructured":"Haltia M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta. 2013;1832(11):1795\u2013800.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"4319_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10545-011-9421-6","volume":"35","author":"J Cialone","year":"2012","unstructured":"Cialone J, Adams H, Augustine EF, Marshall FJ, Kwon JM, Newhouse N, et al. Females experience a more severe disease course in Batten disease. J Inherit Metab Dis. 2012;35(3):549\u201355.","journal-title":"J Inherit Metab Dis"},{"key":"4319_CR9","first-page":"73","volume":"6","author":"JR Ostergaard","year":"2016","unstructured":"Ostergaard JR. Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights. Degener Neurol Neuro. 2016;6:73\u201383.","journal-title":"Degener Neurol Neuro"},{"issue":"1","key":"4319_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/nyas.12990","volume":"1371","author":"MM Ouseph","year":"2016","unstructured":"Ouseph MM, Kleinman ME, Wang QJ. Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease). Ann N Y Acad Sci. 2016;1371(1):55\u201367.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"4319_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.survophthal.2009.04.007","volume":"54","author":"S Bozorg","year":"2009","unstructured":"Bozorg S, Ramirez-Montealegre D, Chung M, Pearce DA. Juvenile neuronal ceroid lipofuscinosis (JNCL) and the eye. Surv Ophthalmol. 2009;54(4):463\u201371.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"4319_CR12","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.bbadis.2013.02.017","volume":"1832","author":"S von Tetzchner","year":"2013","unstructured":"von Tetzchner S, Fosse P, Elmerskog B. Juvenile neuronal ceroid lipofuscinosis and education. Bba-Mol Basis Dis. 2013;1832(11):1894\u2013905.","journal-title":"Bba-Mol Basis Dis"},{"issue":"9","key":"4319_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/0883073813494813","volume":"28","author":"HR Adams","year":"2013","unstructured":"Adams HR, Mink JW, University of Rochester Batten Center Study G. Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease). J Child Neurol. 2013;28(9):1128\u201336.","journal-title":"J Child Neurol"},{"issue":"4","key":"4319_CR14","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/ajmg.a.62607","volume":"188","author":"AN Dang Do","year":"2022","unstructured":"Dang Do AN, Thurm AE, Farmer CA, Soldatos AG, Chlebowski CE, O\u2019Reilly JK, et al. Use of the Vineland-3, a measure of adaptive functioning, in CLN3. Am J Med Genet A. 2022;188(4):1056\u201364.","journal-title":"Am J Med Genet A"},{"issue":"Pt 1","key":"4319_CR15","first-page":"8","volume":"45","author":"S Lamminranta","year":"2001","unstructured":"Lamminranta S, Aberg LE, Autti T, Moren R, Laine T, Kaukoranta J, et al. Neuropsychological test battery in the follow-up of patients with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2001;45(Pt 1):8\u201317.","journal-title":"J Intellect Disabil Res"},{"issue":"4","key":"4319_CR16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/jimd.12366","volume":"44","author":"M Abdennadher","year":"2021","unstructured":"Abdennadher M, Inati S, Soldatos A, Norato G, Baker EH, Thurm A, et al. Seizure phenotype in CLN3 disease and its relation to other neurologic outcome measures. J Inherit Metab Dis. 2021;44(4):1013\u201320.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"4319_CR17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/ajmg.a.62114","volume":"185","author":"H Hildenbrand","year":"2021","unstructured":"Hildenbrand H, Wickstrom J, Parks R, Zampieri C, Nguyen TT, Thurm A, et al. Characterizing upper limb function in the context of activities of daily living in CLN3 disease. Am J Med Genet A. 2021;185(5):1399\u2013413.","journal-title":"Am J Med Genet A"},{"issue":"7","key":"4319_CR18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jamaophthalmol.2016.1000","volume":"134","author":"E Moisseiev","year":"2016","unstructured":"Moisseiev E, Mannis MJ. Evaluation of a Portable Artificial Vision Device Among Patients With Low Vision. Jama Ophthalmol. 2016;134(7):748\u201352.","journal-title":"Jama Ophthalmol"},{"key":"4319_CR19","unstructured":"OrCam. Meet Eli, OrCam\u2019s youngest user. 2015. Available from: https:\/\/www.orcam.com\/en-us\/blog\/meet-eli-orcams-youngest-user."},{"key":"4319_CR20","unstructured":"Foundation PCs. A new way of seeing. Available from: https:\/\/phoenixchildrensfoundation.org\/moments\/bold-ideas\/a-new-way-of-seeing\/."},{"key":"4319_CR21","unstructured":"2 OM. Available from: https:\/\/www.orcam.com\/en-us\/orcam-myeye-2-pro."},{"issue":"6","key":"4319_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0002-9394(00)00610-3","volume":"130","author":"JS Wolffsohn","year":"2000","unstructured":"Wolffsohn JS, Cochrane AL. Design of the low vision quality-of-life questionnaire (LVQOL) and measuring the outcome of low-vision rehabilitation. Am J Ophthalmol. 2000;130(6):793\u2013802.","journal-title":"Am J Ophthalmol"},{"key":"4319_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ajo.2019.01.001","volume":"200","author":"SR Hatt","year":"2019","unstructured":"Hatt SR, Leske DA, Castaneda YS, Wernimont SM, Liebermann L, Cheng-Patel CS, et al. Development of Pediatric Eye Questionnaires for Children With Eye Conditions. Am J Ophthalmol. 2019;200:201\u201317.","journal-title":"Am J Ophthalmol"},{"issue":"23","key":"4319_CR24","doi-asserted-by":"publisher","first-page":"e2436","DOI":"10.1212\/WNL.0000000000009454","volume":"94","author":"MC Masten","year":"2020","unstructured":"Masten MC, Williams JD, Vermilion J, Adams HR, Vierhile A, Collins A, et al. The CLN3 Disease Staging System: A new tool for clinical research in Batten disease. Neurology. 2020;94(23):e2436\u201340.","journal-title":"Neurology"},{"key":"4319_CR25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1365-2788.2006.00804.x","volume":"50","author":"EGC van den Broek","year":"2006","unstructured":"van den Broek EGC, Janssen CGC, van Ramshorst T, Deen L. Visual impairments in people with severe and profound multiple disabilities: an inventory of visual functioning. J Intell Disabil Res. 2006;50:470\u20135.","journal-title":"J Intell Disabil Res"},{"issue":"8","key":"4319_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1755-3768.2007.01158.x","volume":"86","author":"L Sandfeld Nielsen","year":"2008","unstructured":"Sandfeld Nielsen L, Jensen H, Skov L. Risk factors of ophthalmic disorders in children with developmental delay. Acta Ophthalmol. 2008;86(8):877\u201381.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"4319_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/1319-4534.325773","volume":"35","author":"V Hegde","year":"2021","unstructured":"Hegde V, Jain R, Bappal A, Shambhu R. Ocular manifestations in children with developmental delay at a tertiary center in South India. Saudi J Ophthalmol. 2021;35(1):1\u20134.","journal-title":"Saudi J Ophthalmol"},{"issue":"4","key":"4319_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","volume":"33","author":"A Kohlschutter","year":"2019","unstructured":"Kohlschutter A, Schulz A, Bartsch U, Storch S. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses. CNS Drugs. 2019;33(4):315\u201325.","journal-title":"CNS Drugs"},{"key":"4319_CR29","doi-asserted-by":"publisher","first-page":"866983","DOI":"10.3389\/fneur.2022.866983","volume":"13","author":"U Bartsch","year":"2022","unstructured":"Bartsch U, Storch S. Experimental Therapeutic Approaches for the Treatment of Retinal Pathology in Neuronal Ceroid Lipofuscinoses. Front Neurol. 2022;13:866983.","journal-title":"Front Neurol"},{"key":"4319_CR30","unstructured":"T\u00f8ssebro A-G, CA, McElrone D, Cameron J, FMaET. Teaching reading and writing to students with juvenile neuronal ceroid lipofuscinosis. In: von Tetzchner S, Elstad E, T\u00f8ssebro A-G, Rokne S, editors. Juvenile neuronal ceroid lipofuscinosis, childhood dementia and education: intervention, education and learning strategies in a lifetime perspective. Sn\u00f8fugl Forlag; 2019. pp. 257\u201387."},{"key":"4319_CR31","unstructured":"T\u00f8ssebro A-G vTS, Christal A, McElrone D, Siggs M, Oxley JD and Cameron J. Communication and language in education and intervention for children and adults with juvenile neuronal ceroid lipofuscinosis. In: von Tetzchner S, Elstad E, T\u00f8ssebro A-G, Rokne S, editors. Juvenile neuronal ceroid lipofuscinosis, childhood dementia and education: intervention, education and learning strategies in a lifetime perspective. Sn\u00f8fugl Forlag; 2019. pp. 231\u201355."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04319-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:26:58Z","timestamp":1781645218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04319-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4319"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04319-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The National Institutes of Health Institutional Review Board approved the protocols. For the device study (NCT04974307). Appropriate consents or assents were obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}